Home
    Disclaimer
    Bromazepam molecular structure

    Bromazepam Stats & Data

    Zepam Normoc Brozam Lexotan Lexomil lectopam lexilium brazepam
    Chemical Class Benzodiazepine
    Psychoactive Class Depressant
    Half-Life 10-20 hours

    Pharmacology

    DrugBank
    Half-life 10-20 hours Protein binding 70% State Solid Vd 1.56 L/kg Clearance 0.82 mL/min/kg.

    Description

    One of the benzodiazepines that is used in the treatment of anxiety disorders. It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepine.

    Mechanism of Action

    Bromazepam binds to the GABA-A receptor producing a conformational change and potentiating its inhibitory effects. Other neurotransmitters are not influenced.

    Pharmacodynamics

    Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam, like other benzodiazepines, presents a risk of abuse, misuse, and dependence. According to many psychiatric experts, Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.

    Metabolism

    Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes). One of the main metabolites is 3-hydroxybromazepam. It is pharmacologically active and the half life is similar to that of the parent compound.

    Absorption

    Bioavailability is 84% following oral administration. The time to peak plasma level is 1 - 4 hours. Bromazepam is generally well absorbed after oral administration.

    Indication

    For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.

    Elimination

    Urine (69%), as metabolites

    Receptor Profile

    Receptor Actions

    Modulators
    GABA-A receptor positive allosteric modulator (benzodiazepine site)

    History & Culture

    Bromazepam was developed by the Swiss pharmaceutical company Roche, receiving its patent in 1961. The compound was subsequently approved for medical use in 1974, entering the pharmaceutical market as an intermediate-acting anxiolytic medication. Like other benzodiazepines, bromazepam carries recognized concerns regarding misuse and diversion. Research conducted in France examining motor vehicle accidents involving psychotropic substances found that benzodiazepines—particularly diazepam, nordiazepam, and bromazepam—were among the most frequently detected drugs in drivers' blood when combined with alcohol. The substance has also been documented in connection with serious criminal activities, including cases of robbery, homicide, and sexual assault.

    Effect Profile

    Curated + 25 Reports
    Benzodiazepine 8.3

    Strong anxiolysis, cognitive impairment, euphoria, and sedation

    Anxiolysis×3
    10
    Sedation / Relaxation×2
    96.0
    Motor / Cognitive Impairment×1
    101.9
    Euphoria / Mood Lift×1
    107.8
    Catalog Erowid

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    10-20 hours
    Addiction Potential
    Moderate to high. Repeated or long-term use can lead to tolerance, dependence, and a withdrawal syndrome; abrupt cessation risks seizures and severe rebound symptoms.

    Tolerance Decay

    Full tolerance 14d Half tolerance 84d Baseline ~168d

    Clinical and user reports indicate tolerance develops more rapidly to sedative/hypnotic and anticonvulsant effects than to anxiolysis. Exact rates vary widely; the above is a heuristic depiction to discourage frequent redosing and consecutive-day use. After multi‑week use, allow several weeks off for meaningful tolerance reduction before resuming. Data quality is limited and should not substitute for clinical guidance.

    Cross-Tolerances

    Other benzodiazepines
    80% ●●○
    Z-drugs (non‑benzodiazepine hypnotics)
    50% ●○○
    Alcohol (ethanol)
    30% ●○○

    Experience Report Analysis

    Erowid
    25 Reports
    2005–2018 Date Range
    8 With Age Data
    8 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 25 experience reports (25 Erowid)

    25 Reports
    8 Effects Detected
    6 Positive
    2 Adverse
    0 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 6

    Euphoria 52.0% 70%
    Sedation 40.0% 70%
    Anxiety Suppression 40.0% 70%
    Empathy 20.0% 70%
    Focus Enhancement 16.0% 70%
    Tactile Enhancement 16.0% 70%

    Adverse Effects 2

    Memory Suppression 12.0% 70%
    Nausea 12.0% 70%

    Dosage Distribution

    Dose distribution from experience reports

    Median: 6.0 mg IQR: 4.5–18.0 mg n=15

    Real-World Dose Distribution

    62K Doses

    From 25 individual dose entries

    Oral (n=23)

    Median: 6.0mg 25th: 6.0mg 75th: 19.0mg 90th: 24.0mg
    mg/kg median: 0.109 mg/kg 75th: 0.203

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Median: 0.088 mg/kg IQR: 0.06–0.194 mg/kg n=14

    Redose Patterns

    Redosing behavior across 21 reports

    19.0% Redosed
    1.2 Avg Doses

    Benzodiazepine Equivalence

    mg Bromazepam = mg Diazepam
    Bioavailability Oral: 84%.

    Bromazepam - 5-6mg's ~=10mg Diazepam.

    All other CNS depressants.

    Legal Status

    UN Convention on Psychotropic Substances 1971 (Schedule IV)
    Country Status Notes
    Canada Schedule IV CDSA Controlled under the Controlled Drugs and Substances Act. All benzodiazepines, including bromazepam, are regulated as Schedule IV substances requiring a prescription.
    Czech Republic Prescription only Regulated as a prescription medication. Available only through licensed pharmacies with valid medical authorization.
    Germany Prescription only Available by prescription only. Marketed under brand names including Bromazanil (Hexal). Not classified under Anlage listings of the Betäubungsmittelgesetz but regulated as a prescription-only medication.
    Netherlands List II (Opiumwet) Scheduled on List II of the Opium Law. Preparation, possession, delivery, providing, and transport without authorization are prohibited. However, possession of small quantities for personal use is typically not prosecuted, and recreational use itself is not prohibited under Dutch law.
    United States Schedule IV Controlled under the Controlled Substances Act as a Schedule IV depressant. Illegal to sell without a license and illegal to possess without a valid license or prescription.

    Harm Reduction

    drugs.wiki

    Bromazepam is a prescription benzodiazepine anxiolytic that positively modulates GABA-A receptors; it has an oral Tmax of about 1–4 hours and an elimination half-life around 10–20 hours, with an active metabolite (3-hydroxybromazepam). Using it with other CNS depressants (notably alcohol, opioids, GHB/GBL) markedly increases risk of profound sedation and respiratory depression; this combination is overrepresented in overdose data and should be avoided. Co-use with gabapentinoids or Z‑drugs adds sedation and psychomotor impairment; avoid or minimize doses and separate timing if medically unavoidable. Benzodiazepines impair driving and operating machinery; next‑day impairment can persist even when you ‘feel fine’, especially after night dosing or higher doses—do not drive within at least 8–12 hours of a strong dose. Older adults are more sensitive and have slower clearance, increasing falls, fractures, and confusion; doses should be lower and durations shorter. Dependence can develop with weeks of regular use; never stop suddenly after repeated use—taper gradually under medical supervision to avoid severe withdrawal, including seizures. Flumazenil can precipitate acute withdrawal and seizures in dependent or mixed‑overdose settings; its use requires specialist oversight. Avoid in severe respiratory disease, significant hepatic impairment, sleep apnea, or a history of substance use disorder unless closely supervised. In pregnancy or breastfeeding, benzodiazepines are generally avoided unless necessary; if dependent during pregnancy, guidelines favor gradual dose reduction using long‑acting benzodiazepines under specialist care rather than abrupt cessation. Illicit markets in Europe and elsewhere have widespread counterfeit benzodiazepine tablets containing potent ‘designer’ benzos or even synthetic opioids; only use medicine from a verified prescription supply to reduce poisoning risk. Anterograde amnesia, disinhibition, and paradoxical agitation can occur; take initial test doses in a safe setting and avoid decisions, conflict, or public settings while affected.

    References

    ← Back to Bromazepam